মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Rheumatoid arthritis: Filgotin is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotin may be used as monotherapy ... Read moreRheumatoid arthritis: Filgotin is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotin may be used as monotherapy or in combination with methotrexate (MTX). Ulcerative colitis: Filgotin is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Rheumatoid arthritis: The recommended dose of Filgotinib is 200 mg tablet once a day.Ulcerative colitis: The recommended dose of Filgotinib is 200 mg once daily. Patients who have not shown any therapeutic benefit after 22 weeks of treatment should discontinue Filgotinibib. In adults at higher risk of venous thromboembolism, major adverse cardiovascular events and malignancy, the recommended dose for maintenance treatment is 100 mg once daily. In case of flare of the disease, the dose may be escalated to 200 mg once daily. For long term treatment, the lowest effective dose should be used.
পার্শ্বপ্রতিক্রিয়া
The most frequently reported adverse reactions are nausea, upper respiratory tract infection (URTI), urinary tract infection (UTI), dizziness etc.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Immunosuppressive medicinal products: Combination of filgotinib with other potent immunosuppressants such as azathioprine, ciclosporin, tacrolimus, biologic DMARDs (bDMARDs) or other Janus kinase (JAK) inhibitors is not recommended as a risk of additive immunosuppression cannot be excluded.Infections: Infections, including serious infections, have been reported in patients receiving filgotinib. The most frequent serious infection reported with filgotinib was pneumonia. Among opportunistic infections, TB, oesophageal candidiasis, and cryptococcosis were reported with filgotinib.Viral reactivation: Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies. If a patient develops herpes zoster, filgotinib treatment should be temporarily interrupted until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during treatment with filgotinib.Malignancy: The risk of malignancies is increased in patients with rheumatoid arthritis. Immunomodulatory medicinal products may increase the risk of malignancies.Fertility: In animal studies, decreased fertility, impaired spermatogenesis, and histopathological effects on male reproductive organs were observed.Vaccinations: Use of live vaccines during, or immediately prior to, filgotinib treatment is not recommended.Lipids: Treatment with filgotinib was associated with dose-dependent increase in lipid parameters, including total cholesterol, and high-density lipoprotein (HDL) levels, while low-density lipoprotein (LDL) levels were slightly increased.Venous thromboembolism: Consider the risks and benefits prior to treating patients with filgotinib, who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.
নিষেধাজ্ঞা
Hypersensitivity to the active substance or to any of the excipients Active tuberculosis (TB) or active serious infections Pregnancy